Literature DB >> 21131521

Effect of a new probiotic Saccharomyces cerevisiae strain on survival of Escherichia coli O157:H7 in a dynamic gastrointestinal model.

Lucie Etienne-Mesmin1, Valérie Livrelli, Maud Privat, Sylvain Denis, Jean-Michel Cardot, Monique Alric, Stéphanie Blanquet-Diot.   

Abstract

Survival of Escherichia coli O157:H7 was investigated using a dynamic gastrointestinal model. A high bacterial mortality was observed in the stomach and duodenum. In contrast, bacteria grew in the distal parts of the small intestine. The coadministration of Saccharomyces cerevisiae CNCM I-3856 led to a significant reduction of bacterial resumption, maybe through ethanol production.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21131521      PMCID： PMC3028742          DOI： 10.1128/AEM.02130-10

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN： 0099-2240            Impact factor:   4.792


  29 in total

1.  Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic Escherichia coli O157:H7.

Authors:  R J Fitzhenry; D J Pickard; E L Hartland; S Reece; G Dougan; A D Phillips; G Frankel
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Inhibition of in vitro growth of Shiga toxin-producing Escherichia coli O157:H7 by probiotic Lactobacillus strains due to production of lactic acid.

Authors:  M Ogawa; K Shimizu; K Nomoto; R Tanaka; T Hamabata; S Yamasaki; T Takeda; Y Takeda
Journal:  Int J Food Microbiol       Date:  2001-08-15       Impact factor: 5.277

3.  Modelling inactivation of Escherichia coli by low pH: application to passage through the stomach of young and elderly people.

Authors:  K Takumi; R de Jonge; A Havelaar
Journal:  J Appl Microbiol       Date:  2000-12       Impact factor: 3.772

4.  Prevalence and characterization of Shiga toxin-producing Escherichia coli isolated from cattle, food, and children during a one-year prospective study in France.

Authors:  N Pradel; V Livrelli; C De Champs; J B Palcoux; A Reynaud; F Scheutz; J Sirot; B Joly; C Forestier
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

5.  Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment.

Authors:  S Blanquet; J P Meunier; M Minekus; S Marol-Bonnin; M Alric
Journal:  Appl Environ Microbiol       Date:  2003-05       Impact factor: 4.792

6.  A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions.

Authors:  Stéphanie Blanquet; Evelijn Zeijdner; Erick Beyssac; Jean-Philippe Meunier; Sylvain Denis; Robert Havenaar; Monique Alric
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

7.  Fecal shedding of enterohemorrhagic Escherichia coli in weaned calves following treatment with probiotic Escherichia coli.

Authors:  Suzana Tkalcic; Tong Zhao; Barry G Harmon; Michael P Doyle; Cathy A Brown; Ping Zhao
Journal:  J Food Prot       Date:  2003-07       Impact factor: 2.077

8.  Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells.

Authors:  Stephanie Dahan; Guillaume Dalmasso; Veronique Imbert; Jean-Francois Peyron; Patrick Rampal; Dorota Czerucka
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

9.  Ethanol-mediated variations in cellular fatty acid composition and protein profiles of two genotypically different strains of Escherichia coli O157:H7.

Authors:  R Y-Y Chiou; R D Phillips; P Zhao; M P Doyle; L R Beuchat
Journal:  Appl Environ Microbiol       Date:  2004-04       Impact factor: 4.792

10.  An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157 : H7 with bovine intestinal epithelium.

Authors:  Arvind Mahajan; Carol G Currie; Shona Mackie; Jai Tree; Sean McAteer; Iain McKendrick; Tom N McNeilly; Andrew Roe; Roberto M La Ragione; Martin J Woodward; David L Gally; David G E Smith
Journal:  Cell Microbiol       Date:  2008-10-30       Impact factor: 3.715
View more
  22 in total

1.  Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans.

Authors:  Stéphanie Blanquet-Diot; Sylvain Denis; Sandrine Chalancon; Fehd Chaira; Jean-Michel Cardot; Monique Alric
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

2.  Probiotic Activity of a Bacterial Strain Isolated from Ancient Permafrost Against Salmonella Infection in Mice.

Authors:  O Fursova; V Potapov; A Brouchkov; G Pogorelko; G Griva; N Fursova; S Ignatov
Journal:  Probiotics Antimicrob Proteins       Date:  2012-09       Impact factor: 4.609

3.  Role of mucus-bacteria interactions in Enterotoxigenic Escherichia coli (ETEC) H10407 virulence and interplay with human microbiome.

Authors:  Lucie Etienne-Mesmin; Stéphanie Blanquet-Diot; Thomas Sauvaitre; Josefien Van Landuyt; Claude Durif; Charlène Roussel; Adeline Sivignon; Sandrine Chalancon; Ophélie Uriot; Florence Van Herreweghen; Tom Van de Wiele
Journal:  NPJ Biofilms Microbiomes       Date:  2022-10-20       Impact factor: 8.462

4.  Enterohemorrhagic Escherichia coli O157:H7 survival in an in vitro model of the human large intestine and interactions with probiotic yeasts and resident microbiota.

Authors:  Jonathan Thévenot; Lucie Etienne-Mesmin; Sylvain Denis; Sandrine Chalancon; Monique Alric; Valérie Livrelli; Stéphanie Blanquet-Diot
Journal:  Appl Environ Microbiol       Date:  2012-11-30       Impact factor: 4.792

5.  Increased EHEC survival and virulence gene expression indicate an enhanced pathogenicity upon simulated pediatric gastrointestinal conditions.

Authors:  Charlène Roussel; Charlotte Cordonnier; Wessam Galia; Olivier Le Goff; Jonathan Thévenot; Sandrine Chalancon; Monique Alric; Delphine Thevenot-Sergentet; Francoise Leriche; Tom Van de Wiele; Valérie Livrelli; Stéphanie Blanquet-Diot
Journal:  Pediatr Res       Date:  2016-07-18       Impact factor: 3.756

6.  Application of in vitro bioaccessibility and bioavailability methods for calcium, carotenoids, folate, iron, magnesium, polyphenols, zinc, and vitamins B(6), B(12), D, and E.

Authors:  Paz Etcheverry; Michael A Grusak; Lisa E Fleige
Journal:  Front Physiol       Date:  2012-08-06       Impact factor: 4.566

Review 7.  Escherichia coli O157:H7-Clinical aspects and novel treatment approaches.

Authors:  Elias A Rahal; Natalie Kazzi; Farah J Nassar; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2012-11-15       Impact factor: 5.293

8.  Interactions with M cells and macrophages as key steps in the pathogenesis of enterohemorrhagic Escherichia coli infections.

Authors:  Lucie Etienne-Mesmin; Benoit Chassaing; Pierre Sauvanet; Jérémy Denizot; Stéphanie Blanquet-Diot; Arlette Darfeuille-Michaud; Nathalie Pradel; Valérie Livrelli
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

9.  Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 and p38 signaling pathways in intestinal epithelial cells.

Authors:  Galliano Zanello; Mustapha Berri; Joëlle Dupont; Pierre-Yves Sizaret; Romain D'Inca; Henri Salmon; François Meurens
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

10.  Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications.

Authors:  Rima Hatoum; Steve Labrie; Ismail Fliss
Journal:  Front Microbiol       Date:  2012-12-19       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.